These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10858386)

  • 21. Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small cell lung cancer.
    Sioris T; Järvenpää R; Kuukasjärvi P; Helin H; Saarelainen S; Tarkka M
    Eur J Cardiothorac Surg; 2003 Mar; 23(3):403-8. PubMed ID: 12614814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of mediastinoscopy in preoperative evaluation of mediastinal involvement in non-small-cell lung cancer patients with clinical NO disease.
    Gürses A; Turna A; Bedirhan MA; Ozalp T; Kocatürk C; Demir A; Ozcan M; Urer N
    Thorac Cardiovasc Surg; 2002 Jun; 50(3):174-7. PubMed ID: 12077692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prediction model for N2 disease in T1 non-small cell lung cancer.
    Zhang Y; Sun Y; Xiang J; Zhang Y; Hu H; Chen H
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1360-4. PubMed ID: 22819364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China.
    Chen B; Xia W; Wang Z; Zhao H; Li X; Liu L; Liu Y; Hu J; Fu X; Li Y; Xu Y; Liu D; Yang H; Xu L; Jiang F
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2771-2777. PubMed ID: 31428933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe.
    Inoue M; Sawabata N; Takeda S; Ohta M; Ohno Y; Maeda H
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1100-6. PubMed ID: 15052208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer.
    Kamigaichi A; Tsutani Y; Mimae T; Miyata Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
    Clin Lung Cancer; 2021 Mar; 22(2):120-126.e3. PubMed ID: 33485802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved.
    Matsunaga T; Suzuki K; Takamochi K; Oh S
    Eur J Cardiothorac Surg; 2014 Jul; 46(1):86-91. PubMed ID: 24321998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
    Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.
    Li Z; Yu Y; Lu J; Luo Q; Wu C; Liao M; Zheng Y; Ai X; Gu L; Lu S
    J Thorac Oncol; 2009 Jun; 4(6):702-9. PubMed ID: 19404215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Value and limits of conventional mediastinoscopy in preoperative evaluation of primary bronchial cancer].
    Robert J; Rochat T; Savioz D; Ludwig C; Spiliopoulos A
    Schweiz Med Wochenschr; 1998 Jun; 128(23):895-9. PubMed ID: 9658517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe.
    Sakao Y; Okumura S; Mingyon M; Uehara H; Ishikawa Y; Nakagawa K
    J Thorac Oncol; 2011 Mar; 6(3):494-9. PubMed ID: 21266920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.
    Moon Y; Choi SY; Park JK; Lee KY
    World J Surg; 2020 May; 44(5):1658-1665. PubMed ID: 31912252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement.
    Inoue M; Minami M; Shiono H; Sawabata N; Ideguchi K; Okumura M
    J Thorac Cardiovasc Surg; 2006 May; 131(5):988-93. PubMed ID: 16678580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lung cancer staging: the value of ipsilateral scalene lymph node biopsy performed at mediastinoscopy.
    Lee JD; Ginsberg RJ
    Ann Thorac Surg; 1996 Aug; 62(2):338-41. PubMed ID: 8694587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcarinal Lymph Nodes Should be Dissected in All Lobectomies for Non-Small Cell Lung Cancer-Regardless of Primary Tumor Location.
    Eckardt J; Jakobsen E; Licht PB
    Ann Thorac Surg; 2017 Apr; 103(4):1121-1125. PubMed ID: 28109572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan.
    Honguero Martínez AF; García Jiménez MD; García Vicente A; López-Torres Hidalgo J; Colon MJ; van Gómez López O; Soriano Castrejón ÁM; León Atance P
    Rev Esp Med Nucl Imagen Mol; 2016; 35(3):159-64. PubMed ID: 26514322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
    Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
    Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: differences according to histology and smoking status.
    Kato T; Ishikawa K; Aragaki M; Sato M; Okamoto K; Ishibashi T; Oba K; Kaji M
    J Surg Oncol; 2013 May; 107(6):619-24. PubMed ID: 23192365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.